Michael Benkowitz, President and COO of United Therapeutics Corp (NASDAQ:UTHR), recently sold shares totaling approximately $3.73 million. The transactions occurred on November 25, with the sale prices ranging from $368.76 to $376.18 per share. In addition to these sales, Benkowitz also exercised stock options valued at $1.04 million, with exercise prices between $102.11 and $111.00 per share. These transactions were conducted under a pre-established Rule 10b5-1 trading plan.
In other recent news, United Therapeutics Corp. reported robust growth in its third-quarter financial results, with total revenues reaching $748.9 million, a notable increase from the previous year. This growth was largely driven by heightened sales of treprostinil-based products, especially Tyvaso, which exceeded expectations with total sales of $433.8 million. Ladenburg Thalmann, who maintained a neutral rating on the company, lifted their target price to $344 based on these results.
However, not all products met sales expectations. Remodulin sales fell short of projections, while Orenitram and Unituxin sales presented mixed outcomes. Despite these variations, H.C. Wainwright reaffirmed a buy rating on United Therapeutics, raising the price target to $425 due to the company's strategic positioning in the pulmonary arterial hypertension market.
These recent developments reflect United Therapeutics' strategic focus on expanding commercial ventures and research and development. The company has been proactive in securing its market share by initiating contracts with Part D payers, a move that is expected to place the company advantageously when new competitors emerge. The company is also awaiting a potential FDA decision on its Centralized Lung Evaluation System in 2025.
In summary, United Therapeutics continues to focus on its commercial business and research and development, exploring mergers and acquisitions, and returning capital to shareholders, with a goal of reaching a $4 billion revenue run rate by 2025.
InvestingPro Insights
The recent insider selling by United Therapeutics Corp's President and COO Michael Benkowitz comes at a time when the company's stock has shown remarkable performance. According to InvestingPro data, UTHR has experienced a strong return over the last year, with a 63.13% price total return. This aligns with the company's impressive 6-month price total return of 38.16%, indicating sustained momentum in the stock's performance.
Despite the insider selling, United Therapeutics Corp maintains a solid financial position. InvestingPro Tips highlight that the company holds more cash than debt on its balance sheet, suggesting financial stability. Additionally, UTHR boasts impressive gross profit margins, which is reflected in the latest data showing a gross profit margin of 88.94% for the last twelve months as of Q3 2024.
The company's valuation metrics also present an interesting picture. With a P/E ratio of 15.56 and an adjusted P/E ratio of 14.85 for the last twelve months, UTHR appears to be trading at relatively modest multiples considering its growth. This is further supported by an InvestingPro Tip indicating that the stock is trading at a low P/E ratio relative to near-term earnings growth.
For investors seeking more comprehensive analysis, InvestingPro offers 14 additional tips for United Therapeutics Corp, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.